Compositions and methods for adipocyte modulation
    1.
    发明授权
    Compositions and methods for adipocyte modulation 有权
    脂肪细胞调节的组成和方法

    公开(公告)号:US09458086B1

    公开(公告)日:2016-10-04

    申请号:US14322236

    申请日:2014-07-02

    摘要: Modified stilbenoids and formulations thereof are provided. The modified stilbenoids can include one or more amino or amino-alkyl substituents. The formulation can be for the treatment or prevention of obesity and the modified stilbenoid present in an effective amount to alleviate or prevent the onset of one or more symptoms of obesity. Methods of making the modified stilbenoids and formulations thereof are provided. Methods are provided for treating a subject with a modified stilbenoid in an effective amount to alleviate or prevent one or more symptoms associated with diabetes, cardiovascular disease, high blood pressure, deep vein thrombosis, osteoarthritis, obstructive sleep apnea, cancer, and non-alcoholic fatty liver disease. The administration of the modified stilbenoids can result in decreased levels of PKCδII, PKCδVIII, substantially unaltered expression of PKCδI; a decreased number of adipocytes; increased weight and/or fat loss; or a combination thereof.

    摘要翻译: 提供了修饰的芪类化合物及其制剂。 修饰的芪类化合物可以包括一个或多个氨基或氨基 - 烷基取代基。 该制剂可用于治疗或预防肥胖症和有效量的改良的芪类化合物以缓解或预防一种或多种肥胖症状的发生。 提供制备改性芪类化合物及其制剂的方法。 提供了用于以有效量治疗具有修饰的芪类化合物的受试者以减轻或预防与糖尿病,心血管疾病,高血压,深静脉血栓形成,骨关节炎,阻塞性睡眠呼吸暂停,癌症和非酒精性相关的一种或多种症状的方法 脂肪肝病。 修饰的芪类化合物的施用可导致PKCδII,PKCδVIII的水平降低,PKCδI的基本上未改变的表达; 脂肪细胞数量减少; 增加体重和/或脂肪损失; 或其组合。

    ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES
    3.
    发明申请
    ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES 有权
    环磷酸酯和衍生物的抗病毒活性

    公开(公告)号:US20100249230A1

    公开(公告)日:2010-09-30

    申请号:US12797290

    申请日:2010-06-09

    IPC分类号: A61K31/21 A61P31/14 A61P31/16

    CPC分类号: A61K31/216

    摘要: Disclosed is a method of synthesizing new optically pure heterocyclic compounds using Pd(0) catalyzed intramolecular cyclizations. Analogs of cyclopentanes, like isoxazoline-2-oxide and furan, with similar framework to the cyclopentanes act as anti-HIV and anticancer agents which opens a whole new field for application of these compounds. Starting from a meso-diol, optically pure compounds were prepared without utilizing chiral ligands at any stage of the synthesis. The stereochemical outcome of the product (>99% ee) was influenced by desymmetrization catalyzed by Pseudomonas cepacia lipase and the stereo selective nature of the palladium catalyzed transformations.

    摘要翻译: 公开了使用Pd(O)催化的分子内环化合成新的光学纯杂环化合物的方法。 类似于环戊烷类似异恶唑啉-2-氧化物和呋喃的类似物与环戊烷具有相似的框架,起到抗HIV和抗癌剂的作用,为这些化合物的应用开辟了全新的领域。 从内消旋二醇开始,在合成的任何阶段不用手性配体制备光学上纯的化合物。 产物(> 99%ee)的立体化学结果受到洋葱假单胞菌脂肪酶催化的不对称和钯催化转化的立体选择性的影响。

    Formation of cyclopentene nitro-ester and derivatives
    4.
    发明授权
    Formation of cyclopentene nitro-ester and derivatives 有权
    环戊烯硝基酯及其衍生物的形成

    公开(公告)号:US08236853B1

    公开(公告)日:2012-08-07

    申请号:US12327410

    申请日:2008-12-03

    IPC分类号: A61K31/21

    摘要: Disclosed is a method of synthesizing new optically pure heterocyclic compounds using Pd(0) catalyzed intramolecular cyclizations. Analogs of cyclopentanes, like isoxazoline-2-oxide and furan, with similar framework to the cyclopentanes act as anti-HIV and anticancer agents which opens a whole new field for application of these compounds. Starting from a meso-diol, optically pure compounds were prepared without utilizing chiral ligands at any stage of the synthesis. The stereochemical outcome of the product (>99% ee) was influenced by desymmetrization catalyzed by Pseudomonas cepacia lipase and the stereoselective nature of the palladium catalyzed transformations.

    摘要翻译: 公开了使用Pd(O)催化的分子内环化合成新的光学纯杂环化合物的方法。 类似于环戊烷类似异恶唑啉-2-氧化物和呋喃的类似物与环戊烷具有相似的框架,起到抗HIV和抗癌剂的作用,为这些化合物的应用开辟了全新的领域。 从内消旋二醇开始,在合成的任何阶段不用手性配体制备光学上纯的化合物。 产物(> 99%ee)的立体化学结果受到洋葱假单胞菌脂肪酶催化的不对称性和钯催化转化的立体选择性的影响。

    Antiviral activity of cyclopentene nitro-ester and derivatives
    6.
    发明授权
    Antiviral activity of cyclopentene nitro-ester and derivatives 有权
    环戊烯硝基酯及其衍生物的抗病毒活性

    公开(公告)号:US08318804B2

    公开(公告)日:2012-11-27

    申请号:US12797290

    申请日:2010-06-09

    CPC分类号: A61K31/216

    摘要: Disclosed is a method of synthesizing new optically pure heterocyclic compounds using Pd(0) catalyzed intramolecular cyclizations. Analogs of cyclopentanes, like isoxazoline-2-oxide and furan, with similar framework to the cyclopentanes act as anti-HIV and anticancer agents which opens a whole new field for application of these compounds. Starting from a meso-diol, optically pure compounds were prepared without utilizing chiral ligands at any stage of the synthesis. The stereochemical outcome of the product (>99% ee) was influenced by desymmetrization catalyzed by Pseudomonas cepacia lipase and the stereo selective nature of the palladium catalyzed transformations.

    摘要翻译: 公开了使用Pd(O)催化的分子内环化合成新的光学纯杂环化合物的方法。 类似于环戊烷类似异恶唑啉-2-氧化物和呋喃的类似物与环戊烷具有相似的框架,起到抗HIV和抗癌剂的作用,为这些化合物的应用开辟了全新的领域。 从内消旋二醇开始,在合成的任何阶段不用手性配体制备光学上纯的化合物。 产物(> 99%ee)的立体化学结果受到洋葱假单胞菌脂肪酶催化的不对称性和钯催化转化的立体选择性的影响。

    FARNESYLAMINE DERIVATIVES AND METHODS OF USE
    7.
    发明申请
    FARNESYLAMINE DERIVATIVES AND METHODS OF USE 审中-公开
    农药衍生物及其使用方法

    公开(公告)号:US20100227811A1

    公开(公告)日:2010-09-09

    申请号:US12599013

    申请日:2008-05-14

    摘要: The present invention concerns farnesylamine derivatives, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of ras-mediated signal transduction and inhibitors of aberrant cell growth, e.g., as anti-cancer agents, as well as anti-fungal agents. Other non-malignant diseases characterized by proliferation of cells that may be treated using the farneylamine derivatives of the include, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.

    摘要翻译: 本发明涉及法呢基胺衍生物,含有这些化合物的组合物,以及使用这些化合物和组合物作为ras介导的信号转导抑制剂和异常细胞生长抑制剂的方法,例如抗癌剂,以及抗真菌剂 。 以可以使用法呢基胺衍生物治疗的细胞增殖为特征的其它非恶性疾病包括但不限于肝硬化; 移植排斥反应 再狭窄; 以及以T细胞增殖为特征的疾病,例如自身免疫疾病,例如1型糖尿病,狼疮和多发性硬化。